Amgen and AstraZeneca combo cuts lung cancer death risk by 58 percent in Phase 3 trial
Full DeLLphi-305 results show tarlatamab plus durvalumab kept nearly 80 percent of extensive-stage small cell lung cancer patients alive at one year, versus 53 percent on durvalumab alone.